Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Chronic Pancreatitis (CP) Market?
In recent times, there has been a robust growth in the market size of Chronic Pancreatitis (CP). The market, which stood at $4.91 billion in 2024, is projected to expand to $5.25 billion in 2025, resulting in a Compound Annual Growth Rate (CAGR) of 6.7%. Several factors can be credited for the market’s growth during the historic period. They include the growing prevalence of alcohol consumption, an increase in smoking cases, genetic factors and family history, increased awareness about pancreatic diseases, a surge in diabetes cases related to pancreatitis, augmented healthcare expenditure, and enhanced access to healthcare services.
What Growth Rate Is Forecasted for the Chronic Pancreatitis (CP) Market by 2029?
In the upcoming years, the chronic pancreatitis (CP) market is predicted to experience robust growth. The projection is set at a compound annual growth rate (CAGR) of 6.4%, taking the market value up to $6.72 billion by 2029. The factors contributing to the growth in the predicted period could be the increasing aged population, a rise in the necessity of enzyme replacement therapies, the growth in awareness of early diagnosis, health infrastructure growth in emerging markets, the development of new pain management therapies, and an increase in research and clinical trials for treating pancreatitis. Major upcoming trends for the forecast period include the application of artificial intelligence in diagnostic imaging, implementation of minimally invasive surgical techniques, the usage of wearables for constant health monitoring, next-generation sequencing for genetic testing, incorporation of machine learning for tracking disease progression and the creation of smart diagnostic instruments.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp
Which Key Companies Are Shaping the Future of the Chronic Pancreatitis (CP) Market?
Major companies operating in the chronic pancreatitis (CP) market are Pfizer, Johnson & Johnson, Merck & Co Inc, AbbVie Inc, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Baxter, CSL Behring, Octapharma AG, Dr. Reddy’s Laboratories, Nestle Health Science, Cerata Pharmaceuticals, Unichem Laboratories Ltd, LGM Pharma, Aptalis Pharmaceutical Technologies, Digestive Care Inc, Akron Biotech
Which Factors Are Driving Demand in the Chronic Pancreatitis (CP) Industry?
The chronic pancreatitis market is expected to surge due to the rising consumption of alcohol. This use is described as the imbibing of beverages with ethanol, frequently for pleasure, social interaction, or culture. Nevertheless, alcohol dependency or health problems can ensue from overconsumption. Growth in alcohol consumption is spurred by factors such as increased societal acceptance, urbanization, evolving living habits, and stress coping methodologies, predominantly among younger demographics. Alcohol-induced pancreatitis is caused by inflammation and injury to pancreatic cells, leading to fibrosis, blocked ducts, and lasting dysfunction from harmful metabolic waste products. For example, data published by Kirin Holdings Company Limited, a Japanese beer and beverage holding company, in December 2023 indicated a rise in total global beer consumption by around 5.4 million kiloliters (equivalent to around 8.5 billion 633ml bottles) in 2022 compared to 2021, reaching around 192.1 million kiloliters. This rise of approximately 2.9% was credited to the relaxation of COVID-19 effects, accounting for nearly 303.5 billion 633ml bottles. Consequently, the escalating consumption of alcohol is fuelling the chronic pancreatitis market’s expansion.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp
How Is the Chronic Pancreatitis (CP) Market Segmented by Several Divisions?
The chronic pancreatitis (CP) market covered in this report is segmented –
1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Steroids, Antibiotics, Other Treatments
2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Other End Users
Subsegments:
1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids
2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin
3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein
4) By Steroids: Prednisone, Dexamethasone
5) By Antibiotics: Ciprofloxacin, Metronidazole
6) By Other Treatments: Endoscopic Treatment, Surgery
What are the Emerging Market Trends Driving the Growth of the Chronic Pancreatitis (CP) Industry?
Key players in the chronic pancreatitis market are putting their efforts into creating technological breakthroughs such as enzyme replacement therapy to treat exocrine pancreatic insufficiency (EPI), a condition linked with chronic pancreatitis. This treatment method involves patients with inadequate pancreatic function consuming oral pancreatic enzymes to support digestion. For instance, in July 2023, clinical-stage biopharmaceutical firm based in the US, First Wave BioPharma Inc, revealed the results from the Phase 2 SPAN clinical test. The trial was on an improved enteric microgranule delivery formulation of adrulipase aimed at treating exocrine pancreatic insufficiency (EPI) in patients with chronic pancreatitis and cystic fibrosis (CF). Adrulipase is an oral, non-systemic biologic capsule, which is a recombinant lipase enzyme originating from the Yarrowia lipolytica yeast. Its purpose is to disintegrate fat molecules in the digestive system of EPI patients so that it can be absorbed as nutrients.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report
Which Regions Are Driving Growth in the Chronic Pancreatitis (CP) Market?
North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21146
This Report Delivers Insight On:
1. How big is the chronic pancreatitis (cp) market, and how is it changing globally?
2. Who are the major companies in the chronic pancreatitis (cp) market, and how are they performing?
3. What are the key opportunities and risks in the chronic pancreatitis (cp) market right now?
4. Which products or customer segments are growing the most in the chronic pancreatitis (cp) market?
5. What factors are helping or slowing down the growth of the chronic pancreatitis (cp) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model